Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies.

Noam Solomon, co-founder and CEO of Immunai, sits down with Amar Drawid to discuss how the company is using machine learning to take a multi-omics approach to understanding the complexities of the immune system, how it is constructing an atlas of immune cells, and how it is leveraging this to develop the next generation of immunomodulatory drugs.

Behavioral health is one area of medicine that has lagged in the move towards precision medicine, in part because of a lack of high-quality evidence to drive decision-making. Holmusk is working to change that by using AI and real-world data to transform mental health care. Eze Abosi, chief growth officer for Holmusk, sits down with Amar Drawid to discuss the need for standardized ways to measure symptoms for behavioral health conditions. They talk about how Holmusk is unlocking much-needed evidence to guide the successful development of new therapies, how its platform technology works, and why he believes it is charting a path for bringing precision medicines to people with mental health conditions.